Low proportion of pre-treatment Estrogen Receptor (ER) positivity in patients enrolled in a phase II trial of high dose toremifene as a cisplatin (CDDP) modulator in advanced Non-Small Cell Lung Cancer (NSCLC)

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Low proportion of pre-treatment Estrogen Receptor (ER) positivity in patients enrolled in a phase II trial of high dose toremifene as a cisplatin (CDDP) modulator in advanced Non-Small Cell Lung Cancer (NSCLC)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds